183 filings
Page 2 of 10
CORRESP
EVAX
Evaxion Biotech A/S
30 Jan 24
Correspondence with SEC
12:00am
6-K
EVAX
Evaxion Biotech A/S
26 Jan 24
Current report (foreign)
4:30pm
6-K
EVAX
Evaxion Biotech A/S
24 Jan 24
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
2:11pm
SC 13G
EVAX
Evaxion Biotech A/S
23 Jan 24
Evaxion Biotech A/S / Merck & Co. ownership change
3:29pm
6-K
EVAX
Evaxion Biotech A/S
22 Jan 24
Evaxion Announces Completion of ADS Ratio Change
4:45pm
UPLOAD
EVAX
Evaxion Biotech A/S
18 Jan 24
Letter from SEC
12:00am
F-1
EVAX
Evaxion Biotech A/S
12 Jan 24
Registration statement (foreign)
5:17pm
6-K
EVAX
Evaxion Biotech A/S
12 Jan 24
Current report (foreign)
9:24am
6-K
EVAX
Evaxion Biotech A/S
10 Jan 24
Notice of Extraordinary General Meeting
8:44am
6-K
EVAX
Evaxion Biotech A/S
8 Jan 24
Evaxion Announces Plan to Implement ADS Ratio Change
8:30am
6-K
EVAX
Evaxion Biotech A/S
21 Dec 23
Current report (foreign)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
19 Dec 23
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
4:45pm
6-K
EVAX
Evaxion Biotech A/S
19 Dec 23
Evaxion Biotech Announces Private Placement Financing
8:45am
6-K
EVAX
Evaxion Biotech A/S
8 Dec 23
Current report (foreign)
4:45pm
6-K
EVAX
Evaxion Biotech A/S
28 Nov 23
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
8:27am
6-K
EVAX
Evaxion Biotech A/S
17 Nov 23
Current report (foreign)
9:15am
6-K
EVAX
Evaxion Biotech A/S
15 Nov 23
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
8:00am
6-K
EVAX
Evaxion Biotech A/S
6 Nov 23
Current report (foreign)
10:12am
6-K
EVAX
Evaxion Biotech A/S
31 Oct 23
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
11:22am
6-K
EVAX
Evaxion Biotech A/S
26 Oct 23
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
8:30am